Public confidence in FDA up: WSJ

Share this article:

Public confidence in the FDA shows improvement in a new poll but nearly half of Americans still feel the agency does a poor job of ensuring new drug safety and efficacy, The Wall Street Journal reports.

Forty-five percent of Americans surveyed in a Wall Street Journal Online/Harris Interactive health-care poll conducted on May 22-24 said the FDA is doing an excellent or good job in ensuring new prescription drug safety and efficacy.

That number is up from 36% in a poll conducted last year during the aftermath of national settlements over Merck’s painkiller Vioxx and safety recalls from stents and other medical devices. In 2004, 56% said the FDA was doing an excellent or good job.

Forty-nine percent of the nationwide cross section of 2,482 adults surveyed said the FDA is doing a fair or poor job on drug safety. Nearly 58% gave the agency fair to poor ratings on ensuring that innovative drugs come to market more quickly.

A majority of those surveyed said they were confident drug safety would be improved by recently passed Senate legislation to give the FDA new powers to fine drug companies for misleading ads.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...